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Background: Lymphoid cells may express omatostatin receptors (SS-Rs) on their cell sur- 
face. Therefore radiolabeled somatostalin a alogues may be used to visualize SS-R-positive 
lymphoid neoplasms invivo. Exact staging is the basis for treatment decisions in cutaneous 
malignant lymphoma. We considered the possibility that SS-R scintigraphy might offer a 
clinically useful method of diagnostic imaging in patients with cutaneous malignant 
lymphoma. 
Objective: We evaluated SS-R scintigraphy incomparison with conventional staging meth- 
ods in the staging of cutaneous malignant lymphoma. 
Methods: We conducted a prospective study in 14 consecutive patients with histologically 
proven cutaneous malignant lymphoma. SS-R scintigraphy was compared with physical, ra- 
diologic, and bone marrow examinations. Lymph node excisions were performed inpatients 
with palpable lymph nodes. 
Results: SS-R scintigraphy was positive in the lymph nodes in all four patients with malig- 
nant lymph node infiltration and negative in the three patients with dermatopathic lymphade- 
nopathy. In two patients, previously unsuspected lymphoma localizations were visualized by 
SS-R scintigraphy. Inonly three patients all skin lesions were visualized by SS-R scintigra- 
phy; these three patients had not been treated with topical corticosteroids. SS-R scintigraphy 
failed to detect an adrenal mass in one patient and bone marrow infiltration in two patients. 
Conclusion: SS-R scintigraphy may help distinguish dermatopathic lymphadenopathy from 
malignant lymph node infiltration in patients with cutaneous malignant lymphoma. 
0 Am Acad Dermatol 1996;34:985-93.) 
Primary cutaneous lymphomas represent a group 
of non-Hodgkin's lymphomas (NHL) with involve- 
ment of the skin. Cutaneous T-cell lymphomas 
(CTCLs) are more common than cutaneous B-cell 
lymphomas (CBCLs). 1 The most frequent type of 
CTCL is mycosis fungoides. S6zary syndrome oc- 
curs relatively rarely. CTCLs other than mycosis 
fungoides/S6zary syndrome r present approximately 
30% of all CTCLs and are large-cell lymphomas 
with pleomorphic, immunoblastic, or anaplastic 
features.1 The malignant cell in mycosis fungoides 
and S6zary syndrome is a T lymphocyte, which ex- 
presses phenotypic and functional characteristics of 
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helper/inducer T cells. 2' 3 The clinical expression of 
CTCL varies greatly. The disease is slowly progres- 
sive after a long initial phase and eventually may 
progress to involve lymph nodes, visceral organs, 
and peripheral blood or bone marrow. 4,5 
Once the diagnosis of CTCL has been made the 
patient undergoes staging procedures toestimate the 
anatomic extent and localizations of the malignant 
process. The assessment of the extent is critical be- 
cause the stage of disease is the most important 
prognostic factor in patients with CTCL and may 
determine the choice of therapy. 6-1° The role of di- 
agnostic imaging in the staging of CTCL is not well 
established. Only a few reports describe the use of 
imaging modalities in the staging of CTCL. 9, 11-18 
Somatostatin is a peptide hormone consisting of 
14 amino acids. It is present in the hypothalamus, the 
cerebral cortex, the brain stem, the gastrointestinal 
tract, and the pancreas. Somatostatin receptors (SS- 
Rs) have been found on normal human lymphoid 
tissues.19, 2oHigh-affinity SS-Rs have been identi- 
fied in NHLs with the use of in vitro receptor auto- 
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Table I. Clinical characteristics and comparison between somatostatin receptor scintigraphy and 
conventional staging methods in 14 patients with cutaneous malignant lymphoma 
Patient No. 
Sex/Age 
(yr) Diagnosis 
Time between 
diagnosis 
and entry into 
study (mo) 
Time after 
first symptoms 
(yr) 
1 F/67 CTCL: pleomorphic, medium/large 1 4.0 
2 1=/84 CTCL: pleomorphic, small cell/medium 1 0.3 
3 M/52 CTCL: pleomorphic, medimnflarge 2 2.0 
4 M/58 CTCL: pleomorphic, meditun/large, 1 1,5 
5 1=/54 CTCL: MF 1 8.0 
6 M/67 CTCL: MF 1 7.0 
7 M/66 CTCL: MF 45 9.0 
8 F/61 CTCL: S6zary syndrome 1 5.5 
9 M/67 CTCL: MF 1 0.8 
10 MF/1 CTCL: MF 1 20 
11 F/58 CTCL: MF 1 1.0 
12 F/76 CBCL 1 0.7 
13 M/67 CBCL 2 0.4 
14 F/74 CBCL 2 1.0 
BM, Bone marrow; CBCL, cutaneous B-cell lymphoma; CTCL, cutaneous T-cell ymphoma; DLA, dermatopathie lymphadenopathy; F, female; ILC, 
intralesional corticosteroid; M, male; MF, mycosis flmgoides; TC, topical corticosteroid. 
*Staging according to the Dutch Cutaneous Lymphomas Working Group (modified from Fuks). 7,12 
?Concomitant disease actinic reticuloid treated with prednisone. 
$Concomitant disease dermatitis herpetifonnis treated with dapsone. 
radiographic techniques, al 22 On the basis of these 
observations, the radiolabeled somatostatin ana- 
111 1 logue [ In-DTPA-D-Phe ]-octreotide has been ap- 
plied clinically to visualize NHLs in vivo, with no 
toxicity. 2~-24 
We describe the results of a prospective study 
comparing SS-R scintigraphy with conventional 
staging methods in 14 patients with CTCL and 
CBCL. 
PATIENTS AND METHODS 
Between 1991 and 1994, 14 consecutive patients with 
histologically proven CTCL (n = 11) and CBCL (n = 3) 
underwent staging evaluation. The stage of the disease 
was established by physical examination; whole body 
mapping of lesions; chest radiography; computed tomog- 
raphy (CT) of chest, abdomen, and pelvis; bone marrow 
aspiration and biopsy; and analysis of blood smears. CT 
scanning was performed with contiguous 10 mm axial 
sections after oral and intravenous administration f con- 
trast material. Lymph node excisions were performed in
patients with palpable lymph nodes. 
Mycosis fungoides was staged according to a staging 
classification fFuks, 7,12 modified by the Dutch Cutane- 
ous Lymphomas Working Group as follows: stage 1: skin 
involvement only; stage II: skin and dermatopathic 
lymphadenopathy; stage Ili: skin and pathologic lymph 
nodes; stage IV: skin and visceral organ involvement. 
Every stage was subdivided into (a) limited plaques 
<10%, (b) generalized plaques >10%, (c) cutaneous tu- 
mors, and (d) generalized erythroderma. 
The study had been approved by the Ethics Commit- 
tee of the University Hospital Rotterdam. 
Seintigraphy 
SS-R scintigraphy was performed after intravenous 
injection of the radioactive-labeled somatostatin a alogue 
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Previous 
treatment Stage* 
Disease sites by 
conventional methods 
Disease sites by 
SS-R seintigraphy 
TC 
None 
PUVA 
TC 
TC 
TC 
TC 
TC 
LrVB 
TC 
None 
TCt 
TC 
None 
Nones 
TC, ILC 
Ia 
lb 
IVb 
IVc 
IId 
lb 
Skin: macules on total skin and urticaria 
Skin: ulcers and plaques, erythema on legs 
Skin: limited plaques 
DLA (axilla, inguinal) 
Skin: erythroderma 
Lymph nodes (axilla, inguinal) 
Skin: plaques 
Skin: plaques 
Skin: ulcers and plaques 
DLA (neck, axilla, inguinal) 
Skin: erythroderma 
Lymph nodes (inguinal) 
BM 
Skin: tumors 
Lymph nodes (inguinal) 
Adrenal region 
Skin: erythroderma 
DLA (axilla, inguinal) 
Skin: macules 
Skin: ulcers on leg and hips 
Skin: nodule on neck 
Skin: plaques around eye 
Skin negative 
Skin negative 
Sldn positive (only arm) 
DLA negative 
Skin negative 
Lymph nodes positive 
Skin negative 
Skin negative 
Skin negative 
DLA negative 
Synovia positive 
Skin negative 
Lymph nodes positive 
BM negative 
Skin positive 
Lymph nodes positive 
Adrenal region negative 
Skin negative 
DLA negative 
Skin negative 
Skin positive 
Mediastinam positive 
Skin positive 
Skin negative 
[11 lIn_DTPA_D_Phel ]_octreotide] (Mallinckrodt Medical 
BV, Petten, The Netherlands). The preparation of [UlIn- 
DTPA-D-Phel]-octreotide, the dose administered (->200 
MBq), and the technique of scintigraphy with the gamma 
camera, as well as with single photon emission com- 
puted tomography (SPECT) have recently been de- 
scribed. 23,25 Planar total body scintigraphy was per- 
formed 24 hours after injection with a large-field-of-view 
gamma camera (Counterbalance 3700 and ROTA 1I; 
Siemens Gammasonics, Erlangen, Germany) equipped 
with a medium-energy collimator. Repeat scintigrams 
were performed 48 hours after injection when accu- 
mulation of radioactivity in the abdomen was observed 
on the 24-hour scintigrams. Inall patients SPECT images 
of the upper abdomen were made. In normal persons 
a physiologic accumulation of radioactivity may be 
seen in the pituitary and thyroid glands, liver, spleen, 
kidneys, urinary bladder, and occasionally inthe gallblad- 
der. The presence of intestinal radioactivity (mainly in 
the colon at 24 hours) is caused by some hepatobiliary 
clearance of [UiIn-DTPA-D-Phel]-octreotide and can 
be reduced by the use of laxatives. 25,26 The scans 
were evaluated by two investigators (E. P. K. and H. Y. 
O.) who did not know the identity of the patients or 
the results of the conventional staging procedures. Finally 
the results of SS-R scintigraphy and conventional diag- 
nostic tests were compared by the study coordinator (P. 
J. v.d.A.). In case of discrepancies additional radiodiag- 
nostic investigations were scheduled, and if practical and 
possible, histologic verification was attempted. All pa- 
tients were observed uring and after treatment. In three 
patients SS-R scintigraphy was repeated uring follow- 
up. 
RESULTS 
The clinical characteristics of the 14 patients with 
CTCL (n = 11) and CBCL (n = 3) in whom SS-R 
scintigraphy was performed are given in Table I. Ten 
of 14 patients had been treated for long periods with 
topical corticosteroids. 
Pat ients  w i th  CTCL  
SS-R scintigraphy was positive in 5 of 11 patients 
with CTCL. The results of the comparison between 
the sites of disease demonstrated by SS-R scintigra- 
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Table II. Results of physical examination, CT scan, and SS-R scintigraphy in relation with lymph node 
histologic findings in 14 patients with cutaneous malignant lymphoma 
Patient No. 
Physical examination CT scan 
lymph node lymph node 
diameter (cm) diameter (cm) 
1 3 3 
2 Negative Negative 
3 1.5 2 
4 2-3 2-3 
5 Negative Negative 
6 Negative ND 
7 2 1.5-2 
8 2-4 2-4 
9 2 1.8 
10 3 3 
11 Negative Negative 
12 Negative Negative 
13 Negative Negative 
14 Negative Negative 
SS-R seintigraphy 
lymph node areas 
Lymph node 
histologie findings 
Positive* Malignant infiltration 
Negative ND 
Negative Dermatopathic lymphadenopathy 
Positive Malignant infiltration 
Negative ND 
Negative ND 
Negative Dermatopathic lymphadenopathy 
Positive Malignant infiltration 
Positive Malignant infiltration 
Negative Dermatopathic lymphadenopathy 
Negative ND 
Negative ND 
Negative ND 
Negative ND 
CT, Computed tomography; ND, not done; SS-R, somatostalin receptor. 
*Result of SS-R scan during follow-up. 
phy and the conventional staging methods are sum- 
marized in Table I. 
Skin evaluation 
CTCL was limited to the skin in 6 of 11 patients. 
In five of these six patients (i.e., two patients with 
pleomorphic CTCL [patients 1and 2] and three pa- 
tients with mycosis fungoides [patients 5, 6, and 11]), 
SS-R scintigraphy was negative. The skin lesions in 
these patients were macules or plaques. Patient 3 
initially had limited plaques of 0.5 to 10 cm diam- 
eter on multiple sites of the skin. Only one of these 
lesions was visualized on SS-R scintigraphy. 
Five of 11 patients had CTCL in a more advanced 
stage. In only one of these patients were the skin le- 
sions shown by SS-R scintigraphy. This patient (No. 
9) had multiple, sharply marginated, erythematous 
minors on the skin of the face and back (Fig. 1). 
Lymph node evaluation 
The results of physical examination, CT scanning, 
and SS-R scintigraphy in relation to lymph node 
histology are summarized inTable lI. In six patients, 
diseased lymph nodes of 1.5 to 3 cm in diameter 
were palpable at physical examination. Five of these 
patients had generalized lymphadenopathy. These 
enlarged lymph nodes were all apparent on CT scan. 
In three patients SS-R scintigraphy was negative in 
the lymph node areas (patients 3, 7, and 10). Lymph 
node excisional biopsy specimens in these three pa- 
tients showed dermatopathic lymphadenopathy. 
SS-R scintigraphy was positive in the lymph node 
areas in the other three patients (patients 4, 8, and 9; 
Fig. 2). The lymph node excisional biopsy speci- 
mens in these three patients confirmed the involve- 
ment of malignant lymphoma. The sensitivity and 
specificity of the CT scan for malignant lymph node 
infiltration were 100% and 67%, respectively. The 
sensitivity and specificity of SS-R scintigraphy for 
malignant lymph node infiltration were 100% and 
100%, respectively. 
In the 14 patients no lymphadenopathy in the tho- 
rax or abdomen was seen on CT scans of chest, ab- 
domen, and pelvis or by SS-R scintigraphy. 
Organ evaluation 
Dissemination fCTCL to visceral organs or bone 
marrow was seen in three patients. Patient 7 had a 
seronegative arthropathy affecting the hands and 
wrists. SS-R scintigraphy was positive in multiple 
joints (hands, wrists, elbows, knees, and ankles). A 
synovial biopsy specimen showed an infiltrate of 
lymphocytes (exclusively T lymphocytes) and 
plasma cells in a reactive pattern. T-cell receptor 
gene rearrangement analysis was performed on skin 
and synovial specimens, and identical clonal T-cell 
populations were detected in both (data not shown). 
Bone marrow infdtration with S6zary cells (15%) 
was seen in patient 8 but was not apparent on SS-R 
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Fig. 1. A, Patient with mycosis flmgoides, multiple tumors on face. B, Same patient, left 
lateral planar view of head and neck. Normal accumulation f radioactivity in the thyroid. 
Skin tumors clearly visualized (arrows). 
scintigraphy. CT scanning demonstrated a large ad- 
renal mass (5 to 7 cm) in patient 9. Cytologic exam- 
ination of a needle aspiration specimen of the adre- 
nal mass confirmed infiltration with CTCL. SS-R 
scintigraphy was negative in this area. 
SS-R scintigraphy during follow-up 
In three patients with pleomorphic CTCL, SS-R 
scintigraphy was repeated uring follow-up. Patient 
1, with initially negative SS-R scanning, was treated 
with PUVA therapy. Sixteen months later progres- 
sive skin disease had developed as well as lymph 
node and bone marrow infiltration with CTCL. SS-R 
scintigraphy was positive in the peripheral lymph 
node areas, but remained negative in the skin and 
bone marrow. In patient 2 a complete remission was 
reached after CHOP chemotherapy. Eleven months 
later the skin disease recurred (ulcers and plaques). 
SS-R scintigraphy was again entirely negative. The 
skin disease in patient 3, originally showing positiv- 
ity on SS-R scintigraphy, recurred (tumors at multi- 
ple sites) 8 months after PUVA therapy and local 
radiotherapy. On SS-R scintigraphy some skin le- 
sions were positive and some were negative. The 
patient did not respond to different types of chemo- 
therapy and local radiotherapy. SS-R scintigraphy 
performed a third time revealed all active skin 
lesions (tumors). 
Patients with CBCL 
SS-R scintigraphy was positive in two of three 
patients with CBCL (Table I). The skin lesions were 
visualized by SS-R scintigraphy in two patients. In 
patient 12, SS-R scintigraphy also revealed aprevi- 
ously unsuspected localization in the mediastinum 
(Fig. 3, A). On roentgenography and CT of the tho- 
rax (Fig. 3, B) no abnormalities were seen. However, 
this patient had radiologic evidence of mediastinal 
lymphoma 6 months later. Mediastinal lymphoma 
involvement with pericardial infiltration was con- 
firmed at autopsy. In patient 13 the accumulation of
radioactivity in the neck corresponded to a clinically 
evident skin nodule (2 cm) in the neck. SS-R scin- 
tigraphy was entirely negative in the third patient. 
Side effects were not noted in any of the patients 
after the administration of [lllIn-DTPA-D-Phel]- 
octreotide for SS-R scintigraphy. 
DISCUSSION 
The prognosis and treatment of patients with 
CTCL depend on accurate staging. The staging sys- 
tem for CTCL considers the extent of skin involve- 
ment, presence of lymph node or visceral disease, 
and detection of abnormal cells in the peripheral 
blood. In autopsy series, more than 70% of patients 
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Fig. 2. A, CT scan of the thorax of patient with pleomorphic CTCL shows multiple enlarged 
lymph nodes (1.5 to 2 cm in diameter) in the axillary regions (arrows). Lymph node xcision 
biopsy specimen showed malignant ymphoma infiltration. B, Same patient, anterior planar 
thoracic image. Normal accumulation of radioactivity in the thyroid and spleen; abnormal 
accumulation in the axilla (arrow). 
with CTCL have extracutaneous le ions that may 
involve nearly any organ. 6' 27, 28 Despite the high in- 
cidence of extracutaneous CTCL found at autopsy, 
clinically overt extracutaneous di ease, other than 
that involving peripheral lymph nodes and blood, is 
uncommon. 
In the present study, we employed SS-R scintig- 
raphy in i I patients with histologically proven 
CTCL and three patients with CBCL. Among these, 
eight showed a positive SS-R scan. SS-R-positive 
localizations were apparent a different sites of active 
disease in the skin and in extracutaneous di ease. 
Extracutaneous disease in CTCL is frequently 
found in lymph nodes. Histologic interpretation f 
lymph nodes in CTCL is sometimes difficult. Unlike 
the nodes in B-cell lymphomas, most often the nodal 
architecture is preserved and lymph nodes are rarely 
totally replaced by malignant T cells. Furthermore, 
patients with CTCL frequently have benign reactive 
lymphadenopathy or dermatopathic lymphadenopa- 
thy. In dermatopathic lymphadenopathy e para- 
cortical T-cell zones may contain focal accumula- 
tions of atypical convoluted T lymphocytes. South- 
ern blot analysis of the T-cell receptor gene has 
provided evidence of CTCL infiltration in dermato- 
pathic lymph nodes. 29'30 Patients with malignant 
lymph nodes tend to have a shorter survival than pa- 
tients with dermatopathic lymphadenopathy. 9,31If 
malignant lymph node infiltration is apparent, pa- 
tients are usually treated with systemic hemother- 
apy. This is in contrast to patients with dermatopathic 
lymphadenopathy to whom chemotherapy is less 
commonly given. Therefore itis common practice to 
perform lymph node excisions in patients with 
CTCL and peripheral enlarged lymph nodes. In our 
study seven patients initially had or later developed 
enlarged palpable axillary or inguinal lymph nodes. 
SS-R scintigraphy was positive in all four of these 
seven patients with malignant lymph node infiltra- 
tion. All infiltrated lymph nodes were visualized by 
SS-R scintigraphy. The lymph node areas were neg- 
ative on SS-R scintigraphy in the three patients with 
dermatopathic lymphadenopathy. CT does not allow 
differentiation between enlarged peripheral lymph 
nodes with istologic evidence of CTCL and nodes 
demonstrating dermatopathic lymphadenopathy. Al- 
though our series of patients is small, the results 
would suggest that in contrast to other imaging mo- 
dafities SS-R scintigraphy may differentiate b tween 
malignant lymph node infiltration and dermato- 
pathic lymphadenopathy in patients with CTCL. In 
patients with enlarged lymph nodes, a surgical 
lymph node excision might perhaps be avoided on 
the basis of SS-R scintigraphy results. 
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Fig. 3. A, Anterior thoracic planar image in patient with CBCL revealed previously unsus- 
pected lymphoma in mediastinum (arrow). Normal uptake of labeled octreotide is seen in 
the thyroid, liver, spleen. B, Same patient, CT scan of the thorax, no abnormalities were seen. 
Another possible advantage ofSS-R scintigraphy 
is that he whole body is imaged, so that localizations 
not under clinical suspicion can be evaluated. In two 
patients, previously unsuspected lymphoma local- 
izations were revealed by SS-R scintigraphy, that is, 
in the mediastinum and multiple joints. Although in 
patient 7 only reactive T lymphocytes were seen in 
the synovial specimen, clonality of these T lympho- 
cytes was demonstrated byT-cell receptor gene re- 
arrangement analysis. By analogy with the demon- 
stration of clonal T-cell lymphocytic infiltration in 
dermatopathic lymphadenopathy, 29, 30 the presence 
of clonal T lymphocytes alone in the synovia, 
although not sufficient for the diagnosis of malignant 
infdtration with CTCL, is highly suggestive of the 
(pre)malignant character of the infiltrate. 
On the other hand, SS-R scintigraphy failed to 
detect an adrenal mass and bone marrow infdtration. 
The adrenal mass may not have been detected by 
SS-R scintigraphy because of the physiologic uptake 
of the radioligand in the kidneys. This might have 
interfered with the detection of adrenal involvement, 
despite the use of SPECT. The reason that bone 
marrow infiltration was not revealed by SS-R scin- 
tigraphy is unclear. A locally low density of recep- 
tors and unknown local factors may be involved. 
At first sight, SS-R scintigraphy appears of minor 
value in the confirmation of early skin disease in 
CTCL. The skin lesions were visualized in only two 
patients. In both patients the skin disease was in the 
tumor stage. Skin tumors usually develop at later 
stages. Only one of several plaques was detected by 
SS-R scintigraphy inpatient 3. This skin lesion was 
the presenting lesion several years before mycosis 
fungoides was diagnosed. In the other patients no 
accumulation f radioactivity was seen in the plaques. 
We can only speculate as to the reason SS-R scin- 
tigraphy failed to visualize these thin lesions. One 
explanation might be that most of the patients had 
been treated for long periods with topical corticos- 
teroids. Except for patient 3 in whom only one of 
several lesions was visualized by SS-R scintigraphy, 
none of the three other patients in whom the skin le- 
sions were visualized had been treated with opical 
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corticosteroids. The topical administration f corti- 
costeroids might have influenced the SS-R expres- 
sion on the tumor cells. Long-term exposure of rat 
pituitary tumor cells to glucocorticoids has been 
demonstrated to result in downregulation f soma- 
tostatin binding because of a decrease in the number 
of SS-Rs per cell. 32 Dexamethasone tr atment re- 
duced the number of SS-Rs 2.5-fold in a rat pancre- 
atic carcinoma cell line. 33 
SS-R scintigraphy is not specific for visualizing 
tissues infiltrated with malignant lymphomas. Neu- 
roendocrine tumors, granulomatous diseases, and 
autoimmune diseases may be visualized by SS-R 
scintigraphy as well. 23 However, no false-positive 
results were seen in this study. 
SS-R scintigraphy not only indicates the sites of 
involvement ofa malignant process, but it also gives 
information on the expression of SS-Rs. Modest ac- 
tivity of somatostatin as a single agent has been 
demonstrated by Witzig et al.34 in low-grade NHL 
and CTCL. SS-R scintigraphy was not performed 
before or after treatment. I  is tempting to postulate 
that patients who have tumors that are shown by 
SS-R scintigraphy will be most likely to respond to 
therapy with somatostatin or to radiotherapy with a 
somatostatin a alogue coupled to a [3-emitting radi- 
onuclide. 
SS-R scintigraphy appears to provide an indepen- 
dent approach to the evaluation of dissemination f
CTCL and CBCL. Although further studies are nec- 
essary in a larger group of patients before definite 
conclusions can be made, our results suggest hat 
SS-R scintigraphy may be able to distinguish der- 
matopathic lymphadenopathy from marlgnant lymph 
node infiltration in certain patients with CTCL and 
be useful in a complete staging work-up of patients 
with cutaneous malignant lymphomas. 
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